News

Under the deal, BMS will use Five Prime’s platform to move forward its existing immuno-oncology programs by identifying the most viable drug targets for continued research and development.

If successful, both companies will collaborate on developing the imaging flow technology platform for future commercialization in hematology. Currently, Sysmex is conducting a clinical study assessing EMD Millipore’s

Trellis’ discovery platform, called CellSpot, uses computerized microscopy to drastically miniaturize a multiplexed antigen binding assay capable of characterizing millions of individual antibody producing B cells. Hence, CellSpot

The strategic collaboration is designed to support the commercial development of Generx and Excellagen by Taxus Cardium, and also to provide new opportunities to explore the commercialization of

Drs Kratz and Warnecke and their scientific team will expand the Corporation’s novel albumin-binding anti-cancer drug pipeline. Dr Kratz, one of the most highly regarded conjugation chemists in

The company plans to conduct the Phase II study in Israel, Europe and the US and it will include 78 subjects that will be dosed with the drug

Data generated from this agreement will demonstrate the combination of the unique Advaxis immunotherapy platform, which generates both tumor fighting T cells and reduces tumor protection inside the

The company is developing EPI-743 for pediatric and adult mitochondrial disease, including Friedreich’s ataxia. In the recently completed Phase I and multiple Phase II trials, EPI-743 has been

Findings from a pre-specified retrospective analysis of patients showed that talimogene laherparepvec reduced the size of injected tumors and also non-injected tumors that had metastasized to other parts